These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Perspectives of HER2-targeting in gastric and esophageal cancer. Gerson JN; Skariah S; Denlinger CS; Astsaturov I Expert Opin Investig Drugs; 2017 May; 26(5):531-540. PubMed ID: 28387541 [TBL] [Abstract][Full Text] [Related]
11. Molecular-targeted first-line therapy for advanced gastric cancer. Song H; Zhu J; Lu D Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490 [TBL] [Abstract][Full Text] [Related]
12. Current and Future Biomarkers in Esophagogastric Adenocarcinoma. Sappenfield R; Mehlhaff E; Miller D; Ebben JE; Uboha NV J Gastrointest Cancer; 2024 Jun; 55(2):549-558. PubMed ID: 38280174 [TBL] [Abstract][Full Text] [Related]
13. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used? Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459 [No Abstract] [Full Text] [Related]
14. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. Young K; Chau I Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367 [TBL] [Abstract][Full Text] [Related]
15. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Kaur A; Dasanu CA Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344 [TBL] [Abstract][Full Text] [Related]
17. Gastric Carcinoma at the Era of Targeted Therapies. Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma. Cellini F; Valentini V Curr Med Chem; 2014; 21(8):990-1004. PubMed ID: 23992321 [TBL] [Abstract][Full Text] [Related]
19. HER2 testing in gastric cancer: An update. Abrahao-Machado LF; Scapulatempo-Neto C World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694 [TBL] [Abstract][Full Text] [Related]
20. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]